BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Ramius Seeks Hostile Buyout of Cypress Bioscience at $4/Share
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ramius Seeks Hostile Buyout of Cypress Bioscience at $4/Share
July 20, 2010
By
Catherine Hollingsworth
No Comments
Activist shareholder Ramius Value and Opportunity Advisors LLC said that it is seeking to take over Cypress Bioscience Inc., offering to buy the rest of the company shares that it does not already own for $4 per share. (BioWorld Today)
BioWorld